IGF-BP6 Recombinant Protein

IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. IGF-BP6 is produced by bone cells and is the major IGF-BP present in cerebrospinal fluid, and specifically inhibits IGF-II actions. IGF-BP6 has been shown to inhibit IGF-II-dependent cancers such as neuroblastoma, colon cancer and rhabdomyosarcoma. Recombinant human IGF-BP6 has a calculated mass of 22.6 kDa and consists of 213 amino acid residues including the IGF-BP domain and thyroglobulin type-I domain. IGF-BP6 migrates at an apparent molecular weight of approximately 23.0-30.0 kDa by SDS-PAGE analysis under non-reducing conditions.

The lyophilized IGF-BP6 recombinant protein is stable for at least 2 years from date of receipt at -20˚ C. Reconstituted IGF-BP6 is stable for at least 3 months when stored in working aliquots with a carrier protein at -20˚ C. As with any protein, exposing IGF-BP6 recombinant protein to repeated freeze / thaw cycles is not recommended. When working with proteins care should be taken to keep recombinant protein at a cool and stable temperature.